Overview
- Health regulator COFEPRIS has issued an official alert about a confirmed falsified Ozempic lot labeled PP5K617 with an August 2026 expiry and urged people not to use it.
- Novo Nordisk México identified the counterfeit after a technical-document review that found the prefilled pen differs from the genuine FLEXTOUCH device.
- COFEPRIS says there is no certainty about where the product was made, how it was stored or what it contains, which raises the risk of contamination, wrong dosing or other adverse reactions.
- The agency told anyone who bought or used the suspect lot to stop use, seek medical advice for any reactions, report adverse events through pharmacovigilance channels, and report illegal sales to authorities.
- Officials linked the fraud to high consumer demand for semaglutide for weight loss, which has created shortages and encouraged informal sales that can let counterfeit injectable medicines reach patients.